Park Ha Bio plans 1-for-50 reverse stock split

Park Ha Biological Technology Co., Ltd. plans a 1-for-50 reverse stock split effective February 20, 2026, with trading to begin on a split-adjusted basis that day, subject to satisfying Nasdaq Operations notice requirements.

Rhea-AI Filing Summary

Park Ha Biological Technology Co., Ltd. plans a 1-for-50 reverse stock split effective February 20, 2026, with trading to begin on a split-adjusted basis that day, subject to satisfying Nasdaq Operations notice requirements.

To align with this change, the company amended its Memorandum of Association to reduce authorized share capital from USD 3,000,000.00 divided into 150,000,000,000 ordinary shares of par value US$0.00002 each (120,000,000,000 Class A and 30,000,000,000 Class B) to 3,000,000,000 ordinary shares of par value US$0.001 each (2,400,000,000 Class A and 600,000,000 Class B), using the same 1-for-50 ratio as the issued and outstanding shares.

Shareholders approved the reverse split at an extraordinary meeting on December 26, 2026, and the Board of Directors set the exact ratio on January 29, 2026.

Insights

Equity structure analyst

Park Ha Bio consolidates shares 1-for-50 and ups par value.

Park Ha Biological Technology is implementing a 1-for-50 reverse stock split, consolidating every 50 existing shares into one new share, effective February 20, 2026, subject to Nasdaq Operations notice requirements. This typically raises the per-share trading price while keeping overall economic ownership unchanged.

In tandem, the company is reducing authorized ordinary shares from 150,000,000,000 at par US$0.00002 to 3,000,000,000 at par US$0.001, preserving voting rights of Class A (1 vote) and Class B (20 votes). The change follows shareholder approval on December 26, 2026 and board approval on January 29, 2026.

Subsequent disclosures in company filings may provide further detail on how the new capital structure interacts with Nasdaq listing requirements and any future equity-related actions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What reverse stock split did Park Ha Biological Technology (BYAH) approve?

Park Ha Biological Technology approved a 1-for-50 reverse stock split, meaning every 50 existing shares will be consolidated into one new share. The split is planned to take effect February 20, 2026, with trading beginning on a split-adjusted basis that same day.

When will Park Ha Biological Technology (BYAH) start trading on a reverse-split basis?

Trading in Park Ha Biological Technology shares is expected to begin on a split-adjusted basis at market open on February 20, 2026. This follows implementation of the 1-for-50 reverse stock split, subject to the company satisfying Nasdaq Operations notice requirements beforehand.

How is Park Ha Biological Technology (BYAH) changing its authorized share capital?

The company is reducing authorized ordinary shares from 150,000,000,000 at par value US$0.00002 to 3,000,000,000 at par value US$0.001. Class A will total 2,400,000,000 shares and Class B 600,000,000 shares, matching the 1-for-50 reverse split ratio.

Will the Park Ha Biological Technology (BYAH) reverse split affect Class A and Class B voting rights?

The reverse split and capital change keep existing voting structures: Class A ordinary shares retain 1 vote per share, and Class B ordinary shares retain 20 votes per share. Only the number of shares and par value per share are adjusted proportionally at the 1-for-50 ratio.

Who approved the Park Ha Biological Technology (BYAH) reverse stock split and ratio?

A majority of shareholders approved the reverse stock split at an extraordinary meeting on December 26, 2026. The Board of Directors subsequently approved the action and set the exact 1-for-50 ratio on January 29, 2026, leading to the planned February 20, 2026 effectiveness.

What regulatory step is tied to Park Ha Biological Technology (BYAH) implementing its reverse split?

Implementation of the 1-for-50 reverse stock split is subject to the company satisfying Nasdaq Operations notice requirements. Once these conditions are met, trading is expected to commence on a split-adjusted basis at market open on February 20, 2026, according to the company’s disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/09/2026 - 08:52 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File No. 001-42453

PARK HA BIOLOGICAL TECHNOLOGY CO., LTD.

(Translation of registrant’s name into English)

901, Building C
Phase 2, Wuxi International Life Science Innovation Campus
196 Jinghui East Road
Xinwu District, Wuxi, Jiangsu Province
People’s Republic of China 214000 

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒         Form 40-F ☐

On February 9, 2026, Park Ha Biological Technology Co., Ltd. (the “Company”) announced that it expects to implement a 1-for-50 reverse stock split effective February 20, 2026, subject to the Company’s satisfaction of Nasdaq Operations notice requirements, with trading to begin on a split-adjusted basis at the market open on that day.

In connection with the reverse stock split, the Company filed an Amended and Restated Memorandum of Association, included herewith as Exhibit 3.1, with the Registry of Companies of the Cayman Islands on February 4, 2026 to reduce the authorized share capital of the Company from USD 3,000,000.00 divided into divided into 150,000,000,000 ordinary shares of par value US$0.00002 each divided into (i) 120,000,000,000 Class A ordinary shares with a par value of US$0.00002 each with 1 vote per share and (ii) 30,000,000,000 Class B ordinary shares with a par value of US$0.00002 each with 20 votes per share to 3,000,000,000 ordinary shares of par value US$0.001 each divided into (i) 2,400,000,000 Class A ordinary shares with a par value of US$0.001 each with 1 vote per share and (ii) 600,000,000 Class B ordinary shares with a par value of US$0.001 each with 20 votes per share, the reduction at the same ratio as its reduction in the issued and outstanding shares. As approved and authorized by a majority of the shareholders of at an extraordinary meeting of shareholders held on December 26, 2026, the Board of Directors of the Company subsequently approved the reverse stock split and the exact ratio of the reverse stock split on January 29, 2026.

Exhibit No.		Description
3.1		Amended and Restated Memorandum and Articles of Association

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 9, 2026

	Park Ha Biological Technology Co., Ltd.
	By:	/s/ Xiaoqiu Zhang
	Name:	Xiaoqiu Zhang
	Title:	Chief Executive Officer and Chairperson of the Board

2

Filing Exhibits & Attachments

2 documents

Other Documents

• EX-3.1 AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION 217.3 KB
• EX-3 GRAPHIC 68.0 KB